Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Palisade Bio (7NS0) Stock Price & Analysis

7NS0 Stock Chart & Stats

€5.01€0.00(0.00%)
At close: 1:00 AM GMT+1
€7.5€10€12.54 Dec28 Dec29 Jan6 Feb
Day’s Range
EUR 5.01 - EUR 5.36
52-Week Range
EUR 5.01 - EUR 5.36
Previous Close
EUR 5.01
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 181.01M
Enterprise Value
EUR 316.62M
Total Cash (Recent Filing)
EUR 125.17M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
N/A
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-0.05
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

An essentially debt-free balance sheet reduces interest obligations and refinancing exposure while preserving flexibility to fund clinical development. This gives Palisade Bio more time to advance its pipeline and pursue strategic options without the added pressure of material leverage.

Substantial Capital Base

The sizable equity base and elevated asset balance provide a meaningful financial foundation for a development-stage company. Although the business is not yet profitable, this capital structure can support ongoing research, regulatory planning, and potential partnering efforts.

Focused GI Therapeutic Pipeline

A concentrated focus on gastrointestinal disease gives Palisade Bio a clear therapeutic identity and supports specialization across its research and development activities. A defined disease focus can help align clinical work, regulatory planning, and future commercialization or partnering efforts.

Bears Say

Pre-Revenue Business

Palisade Bio has not established recurring revenue, leaving its financial profile dependent on successful clinical development and future commercialization. Until products generate sales, the company lacks operating revenue to offset research costs or demonstrate durable demand.

Widening Net Losses

The sharp expansion in net losses indicates that spending is rising faster than the business is producing financial returns. Persistent and widening losses can consume the capital base, reduce funding flexibility, and increase the importance of successful development milestones.

Increasing Cash Burn

Negative free cash flow in every period means Palisade Bio continues to consume cash rather than fund operations internally. The increase in burn versus 2025 raises the likelihood that additional financing or partnering will be needed to sustain clinical and regulatory activities.

Palisade Bio News

7NS0 FAQ

What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was €5.01 and its highest was €5.36 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is €181.01M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 14 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on Aug 10, 2026. The company reported -€0.045 earnings per share for the quarter, beating the consensus estimate of -€0.047 by €0.002.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 174,270,550 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -€0.045 in its last earnings report, beating expectations of -€0.047. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Palisade Bio?
Hedge funds hold Palisade Bio shares: the largest hedge-fund position in Palisade Bio is 1,800,360,037 shares, and hedge funds decreased their holdings by 110.5K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology